A study of Baricitinib in children and young adults with Juvenile Idiopathic Arthritis (jia) : A Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients from 1 Year to Less than 18 Years Old with Systemic Juvenile Idiopathic Arthritis (sJIA) - JUVE-BALM

Medienart:

Klinische Studie

Erscheinungsjahr:

2023

Erschienen:

2023

Enthalten in:

WHO International Clinical Trials Registry Platform - (2023) vom: 21. Juni Zur Gesamtaufnahme - year:2023

Sprache:

Englisch

Links:

Volltext [kostenfrei]

Themen:

610
Medical Condition: Systemic Juvenile Idiopathic Arthritis (sJIA) MedDRA version: 20.0Level: LLTClassification code 10079454Term: Systemic juvenile idiopathic arthritisSystem Organ Class: 100000004859;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
Phase: Phase 3
Recruitment Status: Authorised-recruitment may be ongoing or finished
Study Type: Interventional

Anmerkungen:

WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 21-11-2019, Last updated: 2023-06-29

ICTRP ID:

EUCTR2017-004495-60-DK
I4V-MC-JAHU
2017-004495-60-FR

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

CTG00491791X